Jeffrey Skaar, PhD


View Jeff Skaar's profile on LinkedIn
Jeff is a Partner with BSP who has led engagements spanning the firm’s Business and Clinical Strategy, Health Economics, and Medical Communications practices. His recent projects include:

Business and Clinical Strategy:

  • Assessed the competitive landscape, reimbursement landscape, and key product attributes required to support the development and launch of a pharmaceutical company’s novel pain medication for the emergency department setting
  • Evaluated the reimbursement landscape and impact of health technology assessments on reimbursement for orphan medications in Europe to inform the development and launch strategies for a pharmaceutical company’s novel medication for arteriovenous fistula creation
  • Analyzed the antipsychotic market and evaluated value propositions for a client’s novel medication in order to inform clinical trial design and improve messaging to drive adoption with physicians and payers
  • Assessed the global market to inform the development and launch of a diagnostic kit for a pharmaceutical and medical device company’s novel infectious disease diagnostic platform
  • Investigated unmet needs and solution preferences for intraoperative margin determination to support the commercialization of an innovative oncology surgery solution recently acquired by a life sciences company

Medical Communications:

  • Developed and executed a publication plan, including abstracts, posters, and manuscripts, to support the launch of a pharmaceutical company’s multiple assets in the neuroscience space
  • Produced a manuscript examining the diagnosis and treatment of infections using an electronic health record (EHR) database to support a pharmaceutical and medical device company’s novel diagnostic platform
  • Led the development of an AMCP dossier to support the adoption of a pharmaceutical company’s novel opioid analgesic medication

Health Economics:

  • Led the development of a budget impact model demonstrating the cost savings associated with a pharmaceutical company’s novel pain medication for use in outpatient surgical settings and the emergency department
  • Developed an economic model to drive adoption of an advanced molecular diagnostic service for oncology patients by demonstrating cost-effectiveness

Jeff graduated magna cum laude from Princeton University with an A.B. in Molecular Biology and obtained his Ph.D. in Virology from Harvard University. His graduate research focused on the role of the ubiquitin ligases in cancer, and his postdoctoral work focused on the intersections of ubiquitin ligases, DNA damage signaling, and transcription termination in cancer. His graduate and postdoctoral work resulted in 19 peer-reviewed publications. In his spare time, Jeff is an avid runner with the North Brooklyn Runners.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.